eligibility_summary
Adults ≥18 with histologically confirmed B‑NHL, prior CAR‑T received or ineligible, relapsed/refractory after ≥2 lines, if post auto‑ or allo‑SCT, ≥6 mo (allo: no GVHD), measurable disease (Lugano), ECOG 0–1. Exclude: investigational drug <30 d, immunodeficiency, active/recent CNS disease, significant cardiac disease, uncontrolled infection. Other cancers allowed only if curatively treated (e.g., NMSC, CIS ≥3 y, other CR ≥5 y, prostate PSA <1).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06544265 tests SynKIR-310, an autologous, gene‑modified cellular immunotherapy (biological). Product: patient T cells transduced to express a CD19‑directed KIR‑CAR (killer immunoglobulin‑like receptor–based chimeric antigen receptor). Mechanism of action: the CAR binds CD19 on malignant B cells, and the KIR‑based intracellular signaling domain triggers T‑cell activation, cytokine release, and cytotoxic killing of CD19+ cells. Targets: CD19 on B‑cell non‑Hodgkin lymphomas (e.g., DLBCL, FL, MZL, MCL, PMBCL), immune pathways engaged include CAR‑mediated T‑cell activation via KIR‑derived signaling motifs. Single IV infusion, Phase 1 FIH dose‑escalation with expansion in relapsed/refractory B‑NHL.